TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Adrenal disease and pregnancy
Key Statistics
- 1 in 3000 — Primary AI prevalence (to 5.5/100,000)
- 9.5% — Current PPGL fetal mortality
- 60% — Cushing’s in pregnancy = adrenal adenoma
Don't-miss facts
-
Adrenal crisis mimics a surgical acute abdomen (pain, vomiting, shock) — treat first, investigate second: IV HC 100 mg 6–8 hourly + 2–3 L 0.9% saline / 5% dextrose saline
-
Prednisolone ≥5–20 mg/day for ≥3 weeks in pregnancy → IV HC 50–100 mg 8-hourly for up to 24 hours intrapartum. Never stop systemic steroids abruptly (oral or inhaled)
-
SST cut-off (≥500–550 nmol/L after 250 micrograms Synacthen) is unreliable in pregnancy — if features are suggestive and the SST is indeterminate, treat and retest postpartum
-
Never give a β-blocker (including labetalol) before α-blockade in PPGL — hypertensive crisis. Crisis agents: IV sodium nitroprusside (first choice), phentolamine, nicardipine
-
PPGL vs pre-eclampsia: paroxysmal hypertension and orthostatic hypotension do not occur in pre-eclampsia; PPGL has no proteinuria/ankle oedema/raised uric acid and can present at any gestation
-
Cushing’s in pregnancy: salivary cortisol/UFC >3× upper limit of normal is diagnostic; gadolinium MRI is contraindicated; avoid ketoconazole and mitotane
-
Dexamethasone should not be used in pregnancy for CAH (not inactivated by 11βHSD2, crosses placenta); continue pre- pregnancy hydrocortisone. Maternal 17-OHP cannot monitor treatment
-
Primary aldosteronism: eplerenone (FDA class B) over spironolactone (feminisation of male fetus, FGR). No adrenal vein sampling in pregnancy. Resect PPGL before 24 weeks
Key numbers
Primary AI: 1 in 3000–5.5 per 100,000; autoimmune 70–90% HC 15–25 mg/day (2–3 doses) + fludrocortisone 0.05–0.1 mg/day
40 mg HC ≡ 0.1 mg fludrocortisone; on prednisolone ↑fludrocortisone 20–30%
Cortisol peaks at 26 weeks; 2–3× non-pregnant at term; diurnal rhythm preserved
Cushing’s: 60% adrenal adenoma in pregnancy; ACTH <4.4 pmol/L adrenal, >4.4 pituitary
Salivary cortisol: T1 <6.9, T2 <7.2, T3 <9.1 nmol/L PA in pregnancy 0.6–0.8%; renin ↑4× by 8 weeks, 7× in T3
CAH: 21-HD 1:500–1:1000; offspring risk 1:120 classical / 1:250 non-classical
CAH: OGTT at 15 weeks, repeat 24–28 weeks; vaginal delivery in 16–42%
PPGL 1:15,000–1:54,000; fetal mortality 9.5% (7% if diagnosed, 17% if missed)
Abbreviation Key
- AI — adrenal insufficiency
- CBG — corticosteroid-binding globulin
- ACTH — adrenocorticotropic hormone
- GC — glucocorticoid
- CRH — corticotropin-/cortisol-releasing hormone
- MC — mineralocorticoid
- HC — hydrocortisone
- 11βHSD2 — 11-β hydroxysteroid dehydrogenase type 2
- SST — short Synacthen stimulation test
- 17-OHP — 17-hydroxyprogesterone
- UFC — urinary free cortisol
- PPGL — phaeochromocytoma and paraganglioma
- PA — primary aldosteronism
- COMT — catechol-O-methyltransferase
- ARR — aldosterone-to-renin ratio
- MEN-2 — multiple endocrine neoplasia type 2
- CAH — congenital adrenal hyperplasia
- NIPT/NIPD — non-invasive prenatal testing/diagnosis
- 21-HD — 21-hydroxylase deficiency
- FGR — fetal growth restriction
Source: Ahmed M, Bashir M, Okunoye GO et al. Adrenal disease and pregnancy: an overview. The Obstetrician & Gynaecologist 2021;23:265–77. doi:10.1111/tog.12761
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).